Drug Search Results
More Filters [+]

Nicorandil

Alternative Names: nicorandil, sigmart
Latest Update: 2024-05-27
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Potassium Channel Opener

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Bangladesh | Denmark | Dominican Republic | Egypt | France | Germany | India | Ireland | Italy | Japan | Korea | Lebanon | Malta | Netherlands | New Zealand | Pakistan | Peru | Portugal | Russia | Saudi Arabia | Slovenia | Sri Lanka | Switzerland | Taiwan | Turkey | Ukraine | United Kingdom | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nicorandil

Countries in Clinic: China

Active Clinical Trial Count: 2

Highest Development Phases

Phase 1: Angina Pectoris

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20231963

P1

Completed

Angina Pectoris

2023-06-01

CTR20230455

P1

Not yet recruiting

Angina Pectoris

None

Recent News Events